Sotrovimab, CAS 2423014-07-5

Product Description: Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease[1][2].

Applications: COVID-19-anti-virus

Formula: N/A

References: [1]Gupta A, et al; COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941-1950. /[2]Case JB, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun. 2022 Jul 2;13(1):3824. /[3]Cathcart A L, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2[J]. biorxiv, 2022: 2021.03. 09.434607. /[4]Aweda TA, et al. In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys. Eur J Nucl Med Mol Imaging. 2022 Oct 28:1–12.

CAS Number: 2423014-07-5

Molecular Weight: N/A

Compound Purity: 95.0

Research Area: Infection

Solubility: 10 mM in DMSO

Target: SARS-CoV

• Artikelnummer: MEXHY-P99340-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99340-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK